Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD

Janis K. Shute, Ermanno Puxeddu, Luigino Calzetta

Research output: Contribution to journalArticlepeer-review

376 Downloads (Pure)

Abstract

In this review, we identify potential targets for the therapeutic effects of heparin in asthma and chronic obstructive pulmonary disease (COPD), consider the safety and delivery modalities of this therapeutic approach. Specifically, we point to the anti-inflammatory, antioxidant and mucolytic effects of unfractionated heparin with potential to modify disease progression in COPD and asthma when administered via the inhaled route. Inhaled heparin may represent an effective add-on therapy in COPD and asthma patient groups, especially when taking into consideration the relative deficiency in endogenous heparin reported in asthma patients.
Original languageEnglish
Pages (from-to)39-45
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume40
Early online date20 Feb 2018
DOIs
Publication statusPublished - 1 Jun 2018

Fingerprint

Dive into the research topics of 'Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD'. Together they form a unique fingerprint.

Cite this